Drug Profile
Dasiprotimut-T - Biovest International
Alternative Names: Autologous immunoglobulin follicular lymphoma idiotype vaccine - Biovest/NCI; B-cell lymphoma vaccine - Biovest; BiovaxID; FNHLId1; LymprevaLatest Information Update: 29 Jun 2021
Price :
$50
*
At a glance
- Originator National Cancer Institute (USA)
- Developer Biovest International; National Cancer Institute (USA)
- Class Cancer vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Follicular lymphoma; Mantle-cell lymphoma
Most Recent Events
- 16 Jun 2021 The National Cancer Institute completes a phase II trial in Mantle cell lymphoma in USA (NCT00005780)
- 12 Jul 2017 Discontinued - Phase-II for Mantle cell lymphoma in USA (SC)
- 12 Jul 2017 Discontinued - Phase-III for Follicular lymphoma (Late-stage disease) in Russia and Ukraine (SC)